PhRMA Embraces Teva Across Brand-Generic Divide
PhRMA accepts Teva's request for membership; BIO rejected Teva five years ago.
You may also be interested in...
Parties have already agreed to sell more than 50 products so far, but are still extending outside date for closing of Teva's acquisition of Allergan's generic business until October.
New CEO Chip Davis wants GPhA sitting at the table in policy debates rather than being on the menu, but industry consolidation means there are fewer dues-paying members to fill the chairs.
Group of 11 companies is focusing on biosimilar reimbursement and educational issues important to market formation.